比较体外冲击波治疗与肌筋膜松解治疗在慢性盆腔疼痛综合征中的有效性:一项随机对照试验的研究方案
本研究为三组随机对照试验方案,拟从东南大学附属中大医院纳入150例慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)患者,等额分配至体外冲击波治疗组、肌筋膜松解治疗组和联合治疗组。研究为期8周(4周治疗期和4周随访期),主要结局为表面肌电图(sEMG)评估和NIH-CPSI的变化,次要结局包括三维量化、剪切波弹性成像(SWE)和交感神经皮肤反应(SSR)测试的变化。
要点
- 拟纳入150例CP/CPPS患者,等额随机分三组比较单用冲击波、单用肌筋膜松解与联合治疗。
- 主要结局为sEMG和NIH-CPSI变化,次要结局包括三维量化、SWE和SSR测试变化。
- 研究周期8周(4周治疗+4周随访),评估时间点为T0、T1、T2和T3。
核心结论
- 本试验将比较单用体外冲击波治疗、单用肌筋膜松解治疗和联合治疗的疗效差异,以选择CP/CPPS患者最合适的治疗选择。
- 将通过比较各客观与主观测量指标(NIH-CPSI评分、sEMG、SWE、SSR)之间的相互关联来分析CP/CPPS可能的发病机制。
研究设计与样本
- 三组随机对照试验(RCT)设计,计划纳入150例来自东南大学附属中大医院的参与者,等额分配至三个干预组。
- 研究持续8周,包括4周治疗期和4周随访期。
主要发现
- 原文为研究方案,尚未报告试验结果。
关键数值与推荐
- 主要结局为表面肌电图(sEMG)评估和NIH-CPSI的变化。
- 次要结局包括三维量化、剪切波弹性成像(SWE)和交感神经皮肤反应(SSR)测试的变化。
- 评估在干预前(T0)、第5次干预前(T1)、第8次干预后即刻(T2)和第8次干预结束后第4周(T3)进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome is a highly prevalent syndrome. Previous studies showed that extracorporeal shockwave therapy and myofascial release therapy could improve the quality of life in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Theoretically, combined therapy with extracorporeal shockwave therapy and myofascial release therapy will likely have significant advantages in treating CP/CPPS. We, therefore, present a protocol for conducting a well-designed randomized controlled trial to compare the efficacy and safety of each therapy. METHODS: The proposed study will be a three-group randomized control trial (RCT) design that includes 150 participants from Zhongda Hospital Affiliated to Southeast University, with equal allocation of participants to the three intervention groups. The study duration will be 8 weeks, which includes a 4-week treatment period and a 4-week follow-up period. The primary outcome will be the changes in surface electromyography (sEMG) assessment and National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI). The secondary outcomes will include the changes in three-dimensional quantification, shear wave elastography (SWE), and sympathetic skin response (SSR) testing. Assessments will be conducted before the intervention (T0), before the 5th intervention (T1), immediately after the 8th intervention (T2), and the 4th week after the end of the 8th intervention (T3). DISCUSSION: This trial will compare the differences in efficacy between single extracorporeal shockwave therapy, single myofascial release therapy, and combined therapy to select the most appropriate treatment option for patients with CP/CPPS. The possible pathogenesis of CP/CPPS would also be analyzed by comparing the intercorrelation between each objective and subjective measurement (NIH-CPSI score, sEMG, SWE, SSR). TRIAL REGISTRATION: The name of the registry: Extracorporeal Shockwave and Myofascial Release Therapy in Chronic Pelvic Pain Syndrome. REGISTRATION NUMBER: NCT05659199. Date of registration: December 2022.
引用
- Huang N, Qin Z, Sun W, et al. Comparing the effectiveness of extracorporeal shockwave therapy and myofascial release therapy in chronic pelvic pain syndrome: study protocol for a randomized controlled trial. Trials. 2023. PMID: 37853420. doi:10.1186/s13063-023-07633-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。